MIDAS
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome (MIDAS)
What will happen during the trial?
The trial will also examine how the body processes the drug. The study is comprised of two parts: Part 1: Participants will receive different doses of momelotinib to find the best dose by evaluating effectiveness in improving red blood cell transfusion requirements and safety. Part 2: Participants will receive dose selected from Part 1 to assess its impact on improving red blood cell transfusion requirements and safety in LR-MDS.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 80 patients (estimated)
- Sponsors
- GlaxoSmithKline
- Tags
- JAK1 Inhibitor, ACVR1 Inhibitor, JAK2 Inhibitor, Randomization
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2170
- NCT Identifier
- NCT06847867
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.